It is with heavy hearts that we announce the passing of our beloved mother and Oma, Elfriede Legendre, who passed away peacefully on January 19. Born in Mindelheim, Germany, on November 2, 1930, ...

To prepare AI agents for office work, the company is asking contractors to upload projects from past jobs, leaving it to them to strip out confidential and personally identifiable information. OpenAI ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The Afghan national suspected of shooting two National Guard members near the White House on Wednesday had worked with the CIA, the agency’s director said, according to Fox News Digital. The comments ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

I was looking over the week’s posts on Hackaday – it’s part of my job after all – and this gem caught my eye: a post about how to make your own RP2040 development board from scratch. And I’ll admit ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Follow 24/7 Wall St. on Google By Joey Frenette Published ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...